News & Videos - ESPERITE - Page 2

Esperite N.V. (ESP): Update to the market on the publication of the Annual Report 2018 Amsterdam, The Netherlands – 28 June 2019 Esperite N.V. announced on 30 April 2019 that the publication of the Annual Report 2018 will be delayed. The Company made significant progress was confident in its ability to publish the Annual Report 2018 and Half Year Results 2018 before the end of June 2019. Despite the entire dedication of the company’s finance team, Esperite has to announce further delays and...

Amsterdam, The Netherlands – 25 June 2019 Esperite N.V. (Euronext: ESP, “Esperite”) announces today that the negotiations with Polski Bank Komórek Macierzystych S.A. (WSE: PBKM, “PBKM”) regarding the proposed sale of substantially all Cryo-Save’s business related to stem cell banking (the Proposed Sale) has been terminated by PBKM. The terms of the Proposed Sale agreed between the respective executive boards of the parties did not receive approval by the supervisory board of PBKM....

Amsterdam, The Netherlands – 14 June 2019 Esperite N.V. (Euronext: ESP, “ Esperite ”) is pleased to announce that it has agreed an extension of the maturity dates for EUR 4,750,000 in unsecured convertible loan notes (the Loan Notes ). Esperite’s CEO, Mr. Frederic Amar, (in)directly holds EUR 3,350,000 of the Loan Notes, the remaining EUR 1,400,000 in Loan Notes are held by third party investors. Under the original terms of most of the Loan Notes, the maturity date was 31 December 2019....

Amsterdam, The Netherlands – 13 June 2019 Esperite N.V. (Euronext: ESP, “Esperite”) announces today that it has resumed negotiations with Polski Bank Komórek Macierzystych S.A. (WSE: PBKM, “PBKM”) regarding the proposed sale of certain assets and liabilities related to Cryo-Save’s stem cell banking business (the Proposed Sale). The negotiations were resumed by Esperite after receiving an expression of renewed interest by PBKM, as announced today by PBKM. As of today, the parties...

Amsterdam, The Netherlands – 04 June 2019 Jouvene’s new innovative offer will empower people with disease prevention, detection, diagnosis, treatment and management. With more than 10,000 diseases and medical conditions linked to DNA mutations, Whole Genome Sequencing is the Gold Standard for Genetic Diagnostic and the way of personalized medicine. By analysing their genetic map, people obtain essential information so that they can make the best decisions regarding disease prevention and...

Amsterdam, The Netherlands – 04 June 2019 Jouvene’s new innovative offer will empower people with disease prevention, detection, diagnosis, treatment and management. With more than 10,000 diseases and medical conditions linked to DNA mutations, Whole Genome Sequencing is the Gold Standard for Genetic Diagnostic and the way of personalized medicine. By analysing their genetic map, people obtain essential information so that they can make the best decisions regarding disease prevention and...

Amsterdam, The Netherlands – 29 May 2019 Esperite N.V. (Euronext: ESP, “Esperite”) announces today that the Memorandum of Understanding (MoU) between Esperite and Polski Bank Komórek Macierzystych S.A. (WSE: PBKM, “PBKM”) regarding the proposed sale of substantially all Cryo-Save’s business related to stem cell banking (the Proposed Sale) has been terminated due to parties’ lack of agreement on the terms of the sale. As a result, the exclusivity granted by Esperite to PBKM in...

Amsterdam, The Netherlands – 19 May 2019 Esperite N.V. (Euronext: ESP, “Esperite”) announces today that it has received a notice from Euronext that its ordinary shares will be transferred to trading group JG, a special segment for securities subject to listing measures. This listing measure was taken pursuant to article 6.9 of the Euronext Rule Book 1 due to the delay in publication of Esperite’s 2018 annual report as announced on 30 April 2019. The listing measure will be effective as...

Amsterdam, The Netherlands – 13 May 2019 Esperite N.V. announced on 30 April 2019 that the publication of the Annual Report 2018 will be delayed. The Company has made significant progress and it is confident in its ability to publish the Annual Report 2018 and Half Year Results 2018 before the end of June 2019. Esperite N.V. with his subsidiary The Cell Factory wants to confirm that the recent adverse situation does not affect the company’s R&D projects in the field of Exosomes and Micro...

Amsterdam, The Netherlands – 30 April 2019 Esperite N.V. announced on 22 February 2019 that the Company had signed an exclusive agreement regarding the potential acquisition (the Proposed Acquisition) of Cryo Save’s family stem cell banking business by PBKM (Famicord Group). The Proposed Acquisition is a key milestone with regard to the future and strategy of the Company and is subject to the outcome of a due diligence process which is a complex operation. As a consequence additional time is...

Amsterdam, The Netherlands – 05 April 2019 Esperite N.V. (Euronext: ESP, “ Esperite ”) announces today a EUR 250,000 private placement of 25 convertible notes with a principal amount of EUR 10,000 each (the “ Notes ”), with 978,260 share subscription warrants attached with a strike price of EUR 0.115 (the “ Warrants ”). The Notes and Warrants were issued to European Select Growth Opportunities Fund, a fund based in Australia (the “ Investor ”). The placement of the Notes and...

CF-MEV-132 drug candidate belongs to the CF-MEV family of anti-inflammatory EV drugs produced by The Cell Factory Amsterdam, The Netherlands – 27 February 2019 The Cell Factory and the University of Padova, Italy have confirmed the long-term therapeutic effect of the CF-MEV-132 drug candidate for the treatment of bronchopulmonary dysplasia (BPD). The results demonstrate a full regeneration of the lungs affected by the BPD by CF-MEV-132 drug and the effect is stable until adulthood. This is an...

Amsterdam, The Netherlands – 26 February 2019 Esperite N.V. (Euronext: ESP, “ Esperite ”) announces today a EUR 280,000 private placement of 28 convertible notes with a principal amount of EUR 10,000 each (the “ Notes ”), with 1,086,206 share subscription warrants attached with a strike price of EUR 0.116 (the “ Warrants ”). The Notes and Warrants were issued to European Select Growth Opportunities Fund, a fund based in Australia (the “ Investor ”). The placement of the Notes...

Amsterdam, the Netherlands – 22 February 2019 Esperite N.V. (Euronext: ESP) and Polski Bank Komórek Macierzystych S.A. (WSE: PBKM) are pleased to announce that they have entered into an Memorandum of Understanding (MoU) regarding the potential acquisition by PBKM of substantially all Cryo-Save’s business related to stem cell banking (the Proposed Acquisition ). The Proposed Acquisition leverages the respective strengths and quality standards of the two publicly traded companies that are...

Amsterdam, The Netherlands - 10 January 2019 Esperite N.V. (Euronext: ESP, "Esperite" or "the Group") announces that today a 24 th Tranche of EUR 230,000 is issued as a private placement of 23 convertible notes (the "Notes") with a principal amount of EUR 10,000 each, with 778,195 share subscription warrants attached (the "Warrants"), under the financing agreement of up to EUR 13.0 million signed between the Group and the European Select Growth Opportunities Fund on 8 March 2017 (the...

Amsterdam, The Netherlands - 30 November 2018 Esperite N.V. (Euronext: ESP, "Esperite" or "the Group") announces that today a 23 rd Tranche of EUR 220,000 is issued as a private placement of 22 convertible notes (the "Notes") with a principal amount of EUR 10,000 each, with 592,814 share subscription warrants attached (the "Warrants"), under the financing agreement of up to EUR 13.0 million signed between the Group and the European Select Growth Opportunities Fund on 8 March 2017 (the...

This investments would put the Company at the pole position on the market with its four Extracellular Vesicles drug candidates for Crohn's, Bronchopulmonary dysplasia, Epilepsy and Stroke Amsterdam, The Netherlands - 29 November 2018 The Cell Factory is expecting to complete the syndicate of investors to secure its Series A round as forecasted in their business planning for Q1 2019. The Cell Factory in collaboration with its academic partners have made a significant progress in pre-clinical...

Amsterdam, the Netherlands - 27 November 2018 Esperite N.V. (Euronext: ESP, " Esperite ") announces that it has convened its Annual General Meeting of Shareholders (" AGM ") to be held on 8 January 2019 at 14:00 hours CET at Hotel NH Amsterdam Barbizon Palace, Prins Hendrikkade 59-72, 1012 AD, Amsterdam, The Netherlands. The AGM's convocation notice, agenda and the explanatory notes to the agenda and further AGM materials can be downloaded from Esperite's website ( www.esperite.com ) and are...

Amsterdam, The Netherlands - 23 November 2018 ESPERITE N.V. (Euronext: ESP, "Esperite", "the Company" or "the Group") has published today its Annual Report for the year ended 31 December 2017. The 2017 Annual Report is now available on the Company's website www.esperite.com . CryoSave's EBITDA turned positive from € -0.7 million to € 1.3 million. Genoma with AGAATA made strong technological progress despite the liquidation of the Swiss Genoma SA. AGAATA in its latest 3 rd version is the...

Amsterdam, The Netherlands - 19 November 2018 Esperite announces that the preparation of its Annual Report 2017 is now under final review by its auditors and should be published before 24 November 2018. About ESPERITE ESPERITE group, listed at Euronext Amsterdam and Paris, is a leading international company in regenerative and precision medicine founded in 2000. To learn more about the ESPERITE Group, or to book an interview with CEO Frédéric Amar: +31 575 548 998 - [email protected] or visit...